Good luck to you Dr Chang and Allogene team!
Allogene Therapeutics’ Post
More Relevant Posts
-
We are encouraged by this positive step forward for autoimmune patients, and we remain excited about the potential of allogeneic CAR T in autoimmune disease. $ALLO
Three people with autoimmune diseases have responded positively to allogeneic CAR-T therapy, marking a first for the "off-the-shelf" cell therapy tech.
In a first, patients with autoimmune diseases respond to allogeneic CAR-T treatment
fiercebiotech.com
-
Investigational AlloCAR T™ products are designed to overcome limitations of today’s autologous therapies and deliver these potentially transformative treatments to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy Explore the Potential of Expanded CAR T Access: Allogene.com/Pipeline
-
We are very excited about the potential of allogeneic #CART in autoimmune disease. We believe our deep understanding of CAR T and differentiated product profile have the potential to meet both the scale of the autoimmune market and the unique needs of these patients where they seek care. $ALLO
NEW: Four in every five patients suffering from autoimmune diseases, such as lupus, myositis or multiple sclerosis, are women. In the worst cases, sufferers can face multiple organ failure and have their lives tragically cut short. But there's hope - in the form of Car-T, a cell therapy approved to treat some blood cancers, which German rheumatologist Prof Georg Schett has redeployed as a treatment for autoimmune diseases, with remarkable results. 14 out of 15 of Schett's patients are in drug-free remission, with his first patient about to cross the five-year milestone. “Dr Schett saved my life,” said Janina Paech, a 24-year-old lupus sufferer who has been in remission since receiving a Car-T, or chimeric antigen receptor cell therapy. But while Schett has renewed excitement about Car-T’s potential after it was first approved for certain blood cancers in 2017, his research has revived debates about safety, manufacturing constraints and cost surrounding the treatment. Only 35,000 lymphoma and leukaemia patients have been treated with Car-T in the US since its approval seven years ago. In comparison, an estimated 204,000 Americans have systemic lupus erythematosus, a severe form of the disease. I wrote about how biotechs like Cabaletta Bio, Kyverna Therapeutics and Allogene Therapeutics are trying to replicate Schett's success, and how startups like Cellares and Ori Biotech are confronting Car-T's manufacturing challenges. With input from Jason C. Foster, Georg Schett, Fabian Gerlinghaus, Peter Maag, Steven Nichtberger, MD, Yatin Suneja and many others.
Cell therapy offers ‘single shot’ hope to autoimmune disease patients
ft.com
-
We are pleased to present a trial in progress poster on our 1L consolidation ALPHA3 trial, which has the potential to redefine the future of CAR T and treatment of LBCL, and expand access in the community cancer setting. Learn more about ALPHA3: https://lnkd.in/g-4H8fkX
-
Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to potentially meet the current and future needs of patients and expand access to treatment. $ALLO #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: Allogene.com/Home
-
We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
-
We are pleased to announce activation of three community cancer centers as first sites open in our pivotal Phase 2 ALPHA3 trial evaluating cema-cel as part of 1L treatment in #LBCL. Patient screening underway at Rocky Mountain Cancer Centers (RMCC), part of the Sarah Cannon Research Institute and US Oncology Network (Colorado), Astera Cancer Care (ACC), part of the OneOncology Network (New Jersey), and Norton Healthcare. #CART #celltherapy Foresight Diagnostics. https://lnkd.in/gRCrNcE9
-
Our own Zach Roberts provides his perspective on how allogeneic CAR T products may be a solution to problems facing autologous CAR T products for patients with #CLL in the latest issue of Cell & Gene. #Immunotherapy #CART
The Path Forward for CLL is Allogeneic https://lnkd.in/euvZhyWK By Zachary J Roberts MD PhD, Executive Vice President, Research & Development, and Chief Medical Officer, Allogene Therapeutics Chronic lymphocytic leukemia (CLL) remains a disease that is managed, not one that is often cured.
-
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene: Allogene.com/Science
-
-
Thrilled to announce the initiation of our groundbreaking 1L consolidation ALPHA3 trial, which has the potential to redefine the future of CAR T and treatment of LBCL, and expand access in the community cancer setting. Foresight Diagnostics $ALLO #CART #celltherapy #immunotherapy Learn more about ALPHA3: https://lnkd.in/g_sxiYVw
Team Lead and Senior Clinical Trial Practitioner of the Cell Therapy/CAR T trials team at University College London Hospitals NHS Foundation Trust
1moCongrats Dr Chang. Are you planning on opening the study in the UK?